
Kura Oncology (KURA) Stock Forecast & Price Target
Kura Oncology (KURA) Analyst Ratings
Bulls say
Kura Oncology Inc. exhibits a positive outlook due to its strong pipeline and significant early commercial momentum, particularly with the initial sales of KOMZIFTI, projected to remain robust into 2026. The company maintains a substantial cash balance of approximately $667 million at the end of 2025, offering the necessary resources and flexibility to advance its clinical and commercial strategies effectively. Moreover, the partnership with Kyowa Kirin is seen as a highly synergistic collaboration, leveraging shared expertise in oncology, which is expected to enhance Kura's market presence in treating hematologic malignancies.
Bears say
Kura Oncology faces significant risks that may hinder its stock performance, including the potential ineffectiveness or safety concerns surrounding key therapies, ziftomenib and tipifarnib, which could lead to halted development. The company's ability to secure funding for continued drug progression is uncertain, and the overall success of its clinical trials remains a major obstacle to achieving projected sales estimates. Furthermore, competitive challenges from existing and emerging therapies, along with the regulatory landscape, add layers of risk that contribute to a negative financial outlook for Kura Oncology.
This aggregate rating is based on analysts' research of Kura Oncology and is not a guaranteed prediction by Public.com or investment advice.
Kura Oncology (KURA) Analyst Forecast & Price Prediction
Start investing in Kura Oncology (KURA)
Order type
Buy in
Order amount
Est. shares
0 shares